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Background: Epidemiological and experimental studies suggest that exposure to ultrafine particles (UFP) might
aggravate the allergic inflammation of the lung in asthmatics.
Methods: We exposed 12 allergic asthmatics in two subgroups in a double-blinded randomized cross-over design,
first to freshly generated ultrafine carbon particles (64 μg/m3; 6.1 ± 0.4 × 105 particles/cm3 for 2 h) and then to
filtered air or vice versa with a 28-day recovery period in-between. Eighteen hours after each exposure, grass pollen
was instilled into a lung lobe via bronchoscopy. Another 24 hours later, inflammatory cells were collected by means
of bronchoalveolar lavage (BAL). (Trial registration: NCT00527462)
Results: For the entire study group, inhalation of UFP by itself had no significant effect on the allergen induced
inflammatory response measured with total cell count as compared to exposure with filtered air (p = 0.188).
However, the subgroup of subjects, which inhaled UFP during the first exposure, exhibited a significant increase in
total BAL cells (p = 0.021), eosinophils (p = 0.031) and monocytes (p = 0.013) after filtered air exposure and
subsequent allergen challenge 28 days later. Additionally, the potential of BAL cells to generate oxidant radicals was
significantly elevated at that time point. The subgroup that was exposed first to filtered air and 28 days later to UFP
did not reveal differences between sessions.
Conclusions: Our data demonstrate that pre-allergen exposure to UFP had no acute effect on the allergic inflammation.
However, the subgroup analysis lead to the speculation that inhaled UFP particles might have a long-term effect on the
inflammatory course in asthmatic patients. This should be reconfirmed in further studies with an appropriate study design
and sufficient number of subjects.
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Epidemiological studies have shown an association be-
tween increased ambient particle concentrations and ad-
verse respiratory and cardiovascular health effects [1-3].
Ultrafine particles (UFP) as a component of ambient parti-
cles, with an aerodynamic diameter < 0.1 μm may contrib-
ute to these health effects [4-7]. UFP are characterized by
a high number and a low mass concentration in the ambi-
ent air. They provide a large surface area per mass for
interaction with biological structures and molecules [8].
Compared to larger particles, they have a higher depos-
ition rate in the peripheral lung and an enhanced capabil-
ity to produce reactive oxygen species [8-11].
Regarding asthma, a disease characterized by airflow
limitation due to chronic airway inflammation, there is a
clear association of particulate air pollution with increas-
ing exacerbations and hospital admissions [12-15]. A
study on subjects with asthma revealed that the concen-
tration of UFP correlated closely with alterations in lung
function [16]. McCreanor et al. [17] showed in a cross-
over study that diesel particles, as the major source of
urban UFP, alter the lung function of asthmatic patients.
These studies suggest that especially patients with aller-
gic asthma are more susceptible to the effect of ultrafine
particle exposure [7,18,19].
Several animal studies have analyzed the effect of UFP
on allergic sensitization. In particular, carbon black, which
resembles the carbonaceous core of diesel exhaust, en-
hanced the sensitization towards a harmless antigen in
several studies [20-22]. Alessandrini et al. demonstrated
that the exposure to ultrafine carbon particles prior to al-
lergen challenge exerts strong adjuvant effects on the
allergic airway inflammation [23].
Controlled clinical exposure studies with carbon UFP
have demonstrated a high pulmonary deposition in healthy
subjects [24], which was further increased in subjects with
asthma [24,25]. These studies demonstrated altered per-
ipheral blood leukocytes distribution and expression of
adhesion molecules. However, short term effects on in-
flammatory cell counts in induced sputum were not ob-
served [25,26]. While these studies included only mild
and stable asthmatics, controlled clinical studies evalu-
ating the effects of UFP on exacerbated allergic airway
inflammation are lacking so far.
Therefore, the aim of this study was to test the hypoth-
esis that pre-exposure to UFP may aggravate an induced
allergic airway inflammation in asthmatic patients. The
study design consisted of a controlled inhalation of ultra-
fine carbon particles or filtered air for two hours which
was followed by a segmental allergen challenge 18 hours
later in mild asthmatics [27]. The particle effect on the
allergic inflammation was compared in a randomized,
double-blind crossover design: Allergic asthmatics were
randomly assigned to two exposure subgroups startingwith either ultrafine carbon particles followed by filtered
air (sequence A), or filtered air followed by ultrafine car-
bon particles (sequence B). The consecutive inhalative ex-
posures were separated by a recovery period of at least
28 days.
Results
Study subjects
Sixteen subjects with allergic asthma were enrolled in
this study of which 15 were randomized (Figure 1). Fi-
nally, only 12 of the randomized subjects (4 women and
8 men in the age of 25–46 years) were included in the
data analysis, since two subjects received only one ex-
posure for personal reasons or illness and one subject
was inadvertently exposed to UFP in both periods. Char-
acteristic of study subjects are shown in Table 1.
No serious adverse events occurred during the study. We
found no significant changes in lung functions parameters
from the baseline during the exposure to UFP or filtered
air, respectively (Figure 2). Furthermore, we observed no
accompanying changes in oxygen saturation during expo-
sures as measured by pulse oximetry (data not shown).
Exposure data
During the exposures with UFP the mean particle mass
and number concentration was 64.3 ± 11.2 μg/m3 with a
mean number concentration of 6.1 ± 0.4 × 105 particles/
cm3, respectively. The median diameter of the UFP was
49.9 ± 2.0 nm with a mean geometric standard deviation
during the exposures of 1.62. During the control expo-
sures with filtered air the mean number concentration
was 89.4 particles/cm3 and the mass concentration was
below detection limit. During all exposures the relative
humidity and temperature were in a range of 41–50%
and 22–23°C, respectively.
Exposure effects on the allergic airway inflammation
To investigate the effect of the exposures on the allergic
inflammation we determined the absolute numbers of
different cell populations and the concentration of medi-
ators in the BAL fluid after segmental challenge of the
lungs with grass pollen extract compared to the control
challenge with saline.
For the primary statistical analysis of the cross-over-
design, we used an analysis of variance model with
mixed effects including the fixed effect of the exposures,
the periods and sequences and the random effect of the
patients within sequences to model the total cell num-
bers. When all data were combined this global analysis
showed no significant treatment differences between the
exposures with UFP and filtered air on the primary end-
point (total cell numbers; p = 0.188) and the key second-
ary endpoint (absolute eosinophil numbers; p = 0.21) in
the BAL fluid after the allergen challenge (Table 2).
Screening of subjects for asthma symptoms and eligibility in 
previous pollen season by Juniper Asthma Control 
Questionnaire® and lung function during a period of 4 weeks
Enrollment (n=16)
Randomization (n=15)
1. bronchoscopy: Allergen challenge
2 hour exposure to 64 µg/m3
ultrafine particles (UFP) (n=8)
2 hour exposure to HEPA filtered air 
(n=7)
1st Period
2. bronchoscopy: Cell sampling by BAL
1. bronchoscopy: Allergen challenge
2. bronchoscopy: Cell sampling by BAL
1. bronchoscopy: Allergen challenge 
2 hour exposure to HEPA filtered 
air (n=7)
2 hour exposure to 64 µg/m3 ultrafine 
particles (UFP) (n=5)
2nd Period
2. bronchoscopy: Cell sampling by BAL
1. bronchoscopy: Allergen challenge
2. bronchoscopy: Cell sampling by BAL
recovery period 28 days
(n=7) Data-Analysis (n=5)
1 subject excluded from analysis 2 subjects excluded from analysis 
(Received two exposures of UFP) (Received only one exposure)
SEQUENCE A SEQUENCE B
Figure 1 Flowchart of the study design.
Table 1 Characteristic of study subjects
Characteristic of study subjects N = 12
Female sex − no. (%) 4 (33.3)
Age − years 38 [34.2;41.5]
Body weight - BMI 25.8 [23.8;27.8]
FEV1 −% predicted value 96.4 [88.8;103.9]
Methacholine PC20 −mg/ml 1.3 [0.3;5.3]
IgE − IU/ml 423.8 [79.0; 768.5]
Segmental allergen dose − SQE 541.8 [237.2;846.3]
Absolute and relative frequencies of women, mean of study subjects and
corresponding 95%-confidence interval for all other baseline characteristics.
Confidence interval for metacholine concentration is computed with
logarithmic transformation; BMI: Body mass index, FEV1: forced expiratory
volume in 1 second, Methacholine PC20:metacholine concentration to induce
a 20% decrease in FEV1, IgE: total serum IgE (immunonglobulin E), SQE:
standard quality unit.
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in the allergic inflammation between the exposures of
UFP and filtered air. We observed a more pronounced
allergic inflammation after exposure with UFP in the
first and filtered air in the second period (sequence A)
compared to the exposure to UFP in the first period for
the primary endpoint (total cells; p = 0.021) and the key
secondary endpoint (absolute eosinophil numbers; (p =
0.031) as well as for monocytes (p = 0.013) (Figure 3,
Table 3). Additionally, the potential of BAL cells to gen-
erate oxygen radicals after stimulation of PMA was sig-
nificantly increased under filtered air in the second
period compared to UFP (Figure 4, p = 0.041). Further-
more, the cytokines/chemokines IL-6, MCP-1, and TNF-
α were significantly elevated at the same time point
(Table 4, p < 0.05).
time [min]
S
e
q
u
e
n
ce
B
S
e
q
u
e
n
ce
A
2,2
2,4
2,6
2,8
3,0
3,2
3,4
3,6
3,8
4,0
4,2
4,4
4,6
F
E
V
1 
  
[L
]
0 30 60 90 120
2,2
2,4
2,6
2,8
3,0
3,2
3,4
3,6
3,8
4,0
4,2
4,4
4,6
F
E
V
1 
  
[L
]
0 30 60 90 120
UFP Filtered Air
Filtered Air
UFP
Figure 2 FEV1 prior and during exposure with UFP and filtered air for exposure sequence A and B.
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2nd Period: UFP) revealed no treatment differences be-
tween UFP and filtered air.
Discussion
We elucidated the pro-allergic effect of UFP on the air-
way inflammation in asthmatics using a two-treatment/
two-period cross-over study design. We observed no sig-
nificant effects of UFP on the allergic inflammation at
24 h after allergen challenge after UFP exposure com-
pared to an exposure with filtered air within the associ-
ated treatment period. The failure to proof an acute UFP
associated effect on the allergic reaction in asthmatics
might be related to the sampling time point of 42 hours,
which was based on previous data from an exposure
study with identical UFP particles in a mouse model of
allergic asthma [23]. However, our post hoc subgroup
analysis revealed that subjects who were first exposed to
UFP and allergen and 28 days later to filtered air andTable 2 Main effect analysis of primary endpoints of the glob
sequence A and B)
Global mixed model main effect a
BAL cells [106] UFP mean (allergen-saline) Filtered air (FA) mean (allergen-sal
Total cells 20.1 45.7
Eosinophils 18.6 38.9
Main effect analysis analyzing total BAL cells and eosinophils using a mixed model wit
random factor. Estimated mean differences (between allergen challenge and saline) of
(UFP) and filtered air (FA) exposure. Additionally, absolute treatment differences betweallergen showed a pronounced increase in inflammatory
response, while patients treated with UFP and filtered
air in the inverted order (sequence B) showed no signifi-
cant effects. Moreover, the observed increased number
of inflammatory cells in the BAL fluid, predominantly
eosinophils and monocytes, were associated with an in-
creased potential of BAL cells to generate oxygen radi-
cals. Additionally, chemokines which are involved in the
recruitment and differentiation of these inflammatory
cells were found to be elevated.
The cross-over design of this study was based on the
assumption from previous clinical exposures studies
with UFP [13,25], that a wash-out period of 28 days is
sufficient to provide two independent treatment periods.
However, in the second period of both treatment se-
quences a trend (p = 0.2) for an increased inflammatory
response was seen. A potential interpretation is, that the
experimental procedures (challenges with clean air/UFP,
bronchoscopies and allergen challenges) of the firstal study design (including all subjects and exposures of
nalysis of the cross-over design
ine) Treatment effect (UFP-FA) 95%-confidence interval p-value
−25.6 −64.4; 13.2 0.188
−20.3 −52.9; 12.2 0.212
h fixed factors exposure, period, sequence, and subjects within sequence as
total cells and absolute eosinophils in BAL are shown 42 h after ultrafine particle
en UFP and filtered air, with 95% confidence levels and p-values are shown.
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Figure 3 Total cells and absolute eosinophils in BAL in the sequence (A): 1st Period: UFP – 2nd Period: Filtered air and sequence (B): 1st
Period: Filtered air – 2nd Period: UFP. Mean ± SD.
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over effect of the experimental session can not be com-
pletely ruled out, although the formal carry-over analysis
of all subjects was not significant (p = 0.2). Therefore,
the negative findings from this study in the global ana-
lysis could be explained by the trend for a carryover ef-
fect between the exposures which may have biased the
study towards the null. The fact however, that in the
subgroup post hoc analysis the inflammatory effects dur-
ing the 2nd exposure period were statistically significant
only for sequence B supports the speculation that the in-
halation of UFP in the first period has an interaction on
the allergen challenge in the second period. Therefore a
wash-out period of 28 days between UFP exposure ses-
sions is not sufficient, when interactions with allergen
are considered. If such carry-over effects can not be
completely ruled out and analysis of subgroups becomes
necessary, small sample sizes in the subgroups (sequence
A: n = 7; sequence B: n = 5) are a major limitation of the
study. Therefore, the results have to be interpreted withcaution and should be used to generate hypotheses for
further investigations.
Despite the limitation of the study, the potential effects
of the UFP on allergic inflammation 28 days after UFP
exposure is an interesting speculation. One could specu-
late that UFP persist in the airways because they evade
effective clearance mechanisms, e.g. the phagocytosis by
alveolar macrophages and the mucociliar clearance, due
to their ultrafine structure compared to larger particles
[28] resulting in an inefficient clearance of inhaled nano-
particles [29,30]. The persistence of UFP might main-
tain the activation of alveolar epithelial cells and
macrophages via their high activity (i.e. oxygen radical
production) leading to an enhanced inflammation when
subjects are exposed to allergens later on. In order to
define potential mechanisms, we have investigated a
series of mediators in the BAL fluid 24 hours following
the allergen challenge.
The increased concentration of the proinflammatory
mediators IL-6, MCP-1 and TNF-alpha found in the BAL
Table 3 Post hoc sequence analysis of total and differential cell count in BAL
Sequence (A): 1st Period: UFP – 2nd Period: Filtered air
BAL Cells [106] UFP mean (allergen-saline) Filtered air mean (allergen-saline) Treatment effect (UFP-FA) 95%-confidence interval p-value
Total cells 13.4 75.1 −61.6 −110.4; −12.8 0.021
Eosinophils 13.2 64.1 −50.9 −95.5; −6.3 0.031
Monocytes 0.9 5.7 −4.8 −8.3; −1.4 0.013
Macrophages 0.3 6.9 −6.6 −18.7; 5.5 0.232
Neutrophils −0.8 1.9 −2.7 −7.6; 2.1 0.219
Lymphocytes 0.0 1.0 −1.0 −3.1; 1.2 0.313
Sequence (B): 1st Period: Filtered air – 2nd Period: UFP
BAL Cells [106] Filtered air mean (allergen-saline) UFP mean (allergen-saline) Treatment effect (UFP-FA) 95%-confidence interval p-value
Total cells 4.5 29.3 24.8 −33.2; 82.8 0.300
Eosinophils 3.7 26.1 22.5 −25.5; 70.4 0.263
Monocytes 0.4 3.5 3.2 −5.7; 12.0 0.377
Macrophages 0.6 0.7 0.1 −5.8; 6.0 0.951
Neutrophils 0.2 1.1 0.8 −2.2; 3.8 0.492
Lymphocytes −0.1 0.6 0.6 −1.9; 3.2 0.531
Sequence analysis using t-test for two paired samples of the exposure sequence. (A) 1st Period: UFP – 2nd Period: Filtered air and (B) 1st Period: Filtered air – 2nd
Period: UFP. Treatment differences between UFP and filtered air.
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immune compartment. As a possible mechanism it could
be speculated that long living macrophages that have
phagocytosed UFP particles at the first exposure might be
primed for a enhanced reaction to a second stimulus,
namely the allergen provocation. Therefore, the macro-
phages might release increased amounts of cytokines after
activation by the T-cell dependent allergic inflammatory
response. The secondary activation of the macrophages by
the allergic cascade would also explain why the levels of
Th2 cytokines were not elevated. However, the proinflam-
matory cytokines could contribute to the attraction of in-
flammatory cells into the airways. Similar data have beenSequence A
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Figure 4 Treatment differences between UFP and filtered air in seque
(B): 1st Period: Filtered air – 2nd Period: UFP on oxidant radical genera
chemiluminescence (RLU: relative luminescence units). Mean ± SD.seen in the lung of an allergic mouse model following ex-
posure to nano particles in the absence and presence of
allergen [31].
No data are available how long UFP persist in human
airways and how long a potential pro-allergic effect
might be seen. In the mouse model of allergic asthma
the study of Alessandrini et al. [23] has shown that the
exposure to UFP prior to allergen challenge exerts
strong adjuvant effect for several days, but data on long
term effects are lacking. In our study only one single
time point, namely 28 days after the UFP inhalation, is
available for analysis. Furthermore, the influence of en-
vironmental particle exposure before the controlledSequence B
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nce (A): 1st Period: UFP – 2nd Period: Filtered air and sequence
tion of BAL cells after PMA stimulation measured via
Table 4 Post hoc sequence analysis of mediators (cytokines and chemokines) in BAL fluid
Sequence(A): 1.Period: UPF – 2.Period: Filtered air
Mediators BAL [pg/ml] UFP mean (allergen-saline) Filtered air (FA) mean (allergen-saline) Treatment effect
(UFP-FA)
95%-confidence interval p-value
IL-6 −3.0 55.0 −58.0 −102.8; −13.1 0.019
MCP-1 38.0 210.0 −171.9 −303.3; −40.6 0.019
TNF-α 0.2 2.1 −1.9 −2.8; −1.0 0.002
Eotaxin 2.3 10.7 −8.4 −18.9; 2.1 0.097
IL10 0.9 7.2 −6.4 −14.3; 1.6 0.099
CD40L 2.4 2.3 0.2 −5.8; 6.1 0.948
GM-CSF 5.5 6.1 −0.6 −5.5; 4.3 0.779
IFN-γ −0.5 0.1 −0.6 −2.5; 1.4 0.527
IL-13 8.8 67.1 −58.3 −137.5; 20.9 0.122
IL-17 0.1 0.3 −0.2 −0.8; 0.4 0.477
IL-2 1.1 1.00 0.1 −3.0; 3.2 0.928
IL-4 1.3 13.0 −11.8 −30.9; 7.4 0.184
IL-5 128.6 73.3 55.4 −313.1; 423.8 0.726
IL-7 −2.0 −0.4 −1.6 −19.0; 15.7 0.827
IL-8 20.9 48.0 −27.1 −96.1; 42.0 0.375
IL-1β −0.1 1.0 −1.1 −2.9; 0.7 0.174
IL12p70 −0.3 0.01 −0.3 −1.0; 0.4 0.356
Sequence(B): 1.Period: Filtered air – 2.Period: UFP
Mediators BAL [pg/ml] Filtered air (FA) mean (allergen-saline) UFP mean (allergen-saline) Treatment effect
(UFP-FA)
95%-confidence interval p-value
IL-6 12.3 30.5 18.2 −19.4; 55.9 0.250
MCP-1 27.4 113.5 86.1 −98.7; 270.9 0.265
TNF-α 0.2 1.3 1.1 −1.4; 3.5 0.289
Eotaxin 0.6 5.7 5. 2 −4.6; 14.9 0.216
IL10 0.9 8.5 7.7 −5.4; 20.8 0.179
CD40L 0.0 0.1 0.1 −0.2; 0.5 0.374
GM-CSF 2.4 2.5 0.1 −1.7; 1.9 0.910
IFN-γ −0.3 0.4 0.6 −0.5; 1.7 0.181
IL-13 3.0 63.5 60.4 −46.7; 167.6 0.192
IL-17 0.0 1.2 1.2 −1.1; 3.4 0.237
IL-2 1.1 4.3 3.1 −9.9; 16.2 0.540
IL-4 0.0 7.8 7.8 −5.5; 21.0 0.178
IL-5 29.0 75.2 46.2 −39.1; 131.4 0.208
IL-7 −1.0 −0.8 0.3 −7.2; 7.8 0.928
IL-8 13.1 21.5 8.4 −28.9; 45.8 0.565
IL-1β −0.1 0.1 0.1 −0.2; 0.5 0.374
IL12p70 −0.5 −0.6 −0.1 −1.1; 0.9 0.803
Sequence analysis using t-test for two paired samples of the exposure sequence. (A) 1st Period: UFP – 2nd Period: Filtered air and (B) 1st Period: Filtered air – 2nd
Period: UFP. Treatment differences between UFP and filtered air.
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controlled and can not be excluded. Therefore, further
studies are necessary which investigate the potential
longterm effect of UFPs on the allergic inflammation.
These studies should be sufficiently powered and thepotential carry-over effects should be avoided in a par-
allel group study design with repeated measurements.
Ideally, the influence of external particle sources
should be controlled or at least monitored throughout
the study.
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This study has expanded the limited available data about
the causality of UFP and health effects, supporting the
speculation that retained UFP might aggravate the re-
sponse to allergens in asthma patients. However, this
should be reconfirmed in further studies with an appro-
priate study design and sufficient number of subjects.Methods
Study design
This randomized, double-blind, cross-over study was
performed from October 2007 to March 2008 out of
the pollen season at the Fraunhofer Institute for Toxicology
and Experimental Medicine (ITEM) in Hannover, Germany.
Allergic asthmatics were randomly assigned to two exposure
subgroups starting with either ultrafine carbon particles
followed by filtered air (sequence A), or filtered air followed
by ultrafine carbon particles (sequence B). Each inhalation
lasted for two hours in an environmental exposure chamber
and was followed by a subsequent segmental allergen chal-
lenge during bronchoscopy 18 hours after the exposures
with a second bronchoscopy 24 hours after allergen chal-
lenge to obtain the BAL cells. The consecutive inhalative ex-
posures were separated by a recovery period of at least
28 days (see Figure 1). The study protocol (ClinicalTrails.
gov Identifier: NCT00527462) was approved by the Ethics
Committee of Hannover Medical School and was con-
ducted in accordance to the Good Clinical Practice and the
declaration of Helsinki. Written informed consent was pro-
vided by all subjects.Randomization and blinding
The randomization code was generated using SAS soft-
ware without blocking and stratification and provided to
the physicists responsible for the generation of the inhal-
ation atmosphere. All study subjects and clinical investi-
gators were unaware about the exposure sequences.Study subjects
Mild asthmatic subjects were recruited from a volunteer data
base. All were non-smokers, allergic to grass pollen and had
shown asthma symptoms in the previous grass pollen season
(controlled by lung function and the Juniper Asthma control
questionnaire©). They were able to abstain from treatment
with corticosteroids, sodium cromoglycate, theophylline, or
leukotriene modifiers and had no respiratory tract infections
within 4 weeks before the start of the study procedures. Dur-
ing the study the subjects only used β2-agonists for relief of
asthma symptoms, if needed. The airway hyperresponsive-
ness to methacholine was determined 7 days prior to the
first exposure session (see Table 1).Exposures to UFP and filtered air
The asthmatic subjects were exposed to a concentration
of 64 μg/m3 UFP by oral breathing (with nose clip) for
two hours in an environmental exposure chamber. Dur-
ing the exposures they performed an intermittent bicycle
exercise with alternating 15 min periods of exercise and
rest at an intensity adjusted to increase the minute ven-
tilation to 20 L/min/m2. The dose of deposited particles
was calculated to be equivalent to a 24 hours exposure
in central urban regions in the western hemisphere. In
urban air, the persistent insoluble part of the ultrafine
particle concentration is primarily related to soot emit-
ted from combustion processes. The soot concentration
in Berlin, measured in the vicinity of major roads, ranges
between 6.5 and 8 μg/m3 (annual mean values in the
years 2000–2004) [32]. The artificially generated soot
particles are similar in size and morphology to the soot
particles freshly emitted by the road traffic. Assuming a
daily 24 h exposure to 6.5 - 8 μg/m3 for people living in
the vicinity of major roads would cause the same lung
dose in volunteers exposed for 2 h to 78 – 96 μg/m3.
Thus the selected concentration of 64 μg/m3 is slightly
below but in the same range as the daily intake of people
living close to major roads. To minimize interference
from inhalation of high ambient particle concentrations
(e.g. due to diesel (traffic) or cigarette smoke exposure)
immediately prior to the controlled exposure sessions
the subjects stayed overnight in the institute prior to the
subsequent segmental allergen challenge.
The control exposure session also lasted for two hours
and was performed under identical conditions as the
UFP exposure except for using filtered air downstream
of high efficiency particle filters (HEPA filter). Hence-
forth, we refer to an UFP exposure followed by a clean
air exposure as sequence A and to the inverse order of
exposure types as sequence B.
Generation and monitoring of UFP
In this study feshly generated carbon UFP were used for
ambient urban UFP, which is dominated by motor en-
gine combustion.
UFP were generated by electric spark discharge with a
modified particle generator (Type GFG 1000, Palas,
Germany) using highly purified elemental graphite elec-
trodes in an argon atmosphere. The original spark dis-
charge chamber was replaced by an inert ceramic chamber
to avoid organic contamination of the carbon particles, as
previously described [33,34]. The carbon aerosol was gener-
ated at a production rate of 3 mg/h, electrically neutralized
and transported at a volume flow rate of 3–8 L/min into
the environmental exposure chamber (V = 15.5 m3) with
walls of stainless steel. In order to achieve a concentration
of 64 μg/m3 UFP, the chamber was ventilated with a dilu-
tion air stream (HEPA filtered) adjusted to 60 m3/h
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pull ventilation system. The temperature and the relative
humidity were in the range of 22–25°C and 40–60%, re-
spectively. The air conditioning parameters were continu-
ously measured by calibrated sensors.
The number-size distribution of the UFP in the exposure
chamber was monitored continuously (once every 5 min)
using an electrical mobility spectrometer (Model 3071/
3025, TSI, USA). A condensation nucleus counter (Model
3010, TSI, USA) was used to measure 5-min average values
of the total number concentration. Furthermore, cumula-
tive filter samples were collected during the entire exposure
period and the particle mass concentration was measured
by gravimetrical analysis of the filter-deposited particle
mass and the cumulative sampling volume.Safety assessments during exposure session
Pulmonary function and blood pressure were measured
every 30 minutes during the exposure with a hand-held
asthma monitor (AM1®, CareFusion, Germany) and tele-
metric blood pressure meter, respectively. Additionally,
the oxygen saturation and heart rate was monitored con-
tinuously via telemetric pulse oximetry and electrocar-
diogram (ECG), respectively.Bronchoscopy and segmental allergen challenge
Eighteen hours after the exposure to UFP or filtered air,
a first bronchoscopy was performed. Following baseline
bronchoalveolar lavage (BAL) in the left lower lobe, al-
lergen (grass pollen extract; ALK Scherax, Germany) in
a volume of 10 ml saline solution as well as 10 ml saline
solution as a control challenge were instilled in the con-
tra lateral lung segments (Table 1), as previously de-
scribed [35]. Twenty-four hours later, during a second
bronchoscopy, BAL was performed in the allergen- and
saline-challenged segments. The individual dose of aller-
gen was calculated by a skin prick test performed with a
10-fold-dilution series of the allergen extract as previ-
ously described. The bronchoscopies were conducted
under continued oxygen supplementation by certified
pneumologists after premedication with midazolam ac-
cording to a standard protocol following international
recommendations for fiberoptic bronchoscopy (NHLBI
workshop 1991) [36]. During the bronchoscopic proced-
ure and the respective safety monitoring period there-
after, all subjects were continuously monitored with a
three-lead ECG and pulse oximetry. Lung function
measurement was performed prior to discharge of the
patient. Subsequent home monitoring of the lung func-
tion was done by the subjects at home every two hours
until bedtime and the next morning using a hand-held
asthma monitor.Processing and staining of BAL cells
BAL fluid samples were processed as previously described
[37]. In brief, the BAL was centrifuged and the super-
natant was stored at −80°C. The total nucleated cell count
was determined using a Neubauer hemocytometer. Differ-
ential cell counts were obtained using Diff-Quick staining
(Dade Behring Inc., Marburg, Germany). For the ana-
lysis of monocytes, flow cytometric BAL cell differenti-
ation was performed using a Cytomics™ FC 500
cytometer (Beckman Coulter).
Oxygen radical generation of BAL cells
The production of reactive oxygen species by BAL cells
was determined by measuring the chemiluminescence of
lucigenin-loaded cells after stimulation as follows. BAL
cells, at a concentration of 1 × 106/ml, were incubated
(30 minutes, 37°C) in HEPES-buffered RPMI with 5%
AB serum containing 0.6 mM lucigenin (Sigma, Tauf-
kirchen, Germany). Then, the response of the BAL cells
to medium (control) or 10 μM PMA over a period of
30 minutes was determined. The data were expressed as
integrated relative light units (RLU). This test determines
the production of oxygen radicals by BAL cells upon non-
specific mitogenic stimulation. The readout reflects the
cellular composition of the BAL samples (e.g. eosinophils
produce more oxygen radicals) and the activation status of
the cells herein.
Biochemical analysis of BAL fluid
The concentration of cytokines and chemokines in the
BAL fluid was determined with a BIO-PLEX Protein Array
System (BIO-RAD Laboratories, USA) with premixed
antibody-coated microsphere beads (Millipore, USA) ac-
cording to the manufacturer’s recommendations.
Statistical analysis
The primary hypothesis of the two-treatment (the expo-
sures)/two-period cross-over study was to show a signifi-
cant difference of the allergen effect depending on
whether a subject was pre-exposed to UFP or to filtered
air. For each subject the allergen effect is represented by
the difference of the measurements between the lung
segment instilled with allergen and the segment instilled
with saline. The primary endpoint was the number of
total BAL cells. The key secondary endpoint was the
number of eosinophils in the BAL fluid. For the primary
analysis estimates and 95% confidence intervals for the
allergen effect (UFP (allergen-saline)↔ filtered air (aller-
gen-saline)) were estimated in an analysis of variance
with linear mixed effects consisting of the fixed factors
of exposure, period, sequence, and subjects within se-
quence as a random factor.
Descriptive analyses include means and standard devi-
ations for each sequence and period. Paired t-tests were
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between periods descriptively. Results were considered
to be significant at a P value of <0.05. All data analyses
were performed with SAS software, version 9.2.
Sample size estimation was based on the paired t-test.
No prior information on the standard deviations was avail-
able, however it was assumed that an effect size of δ =¾ =
0.75 would be of clinical relevance. Thus, a sample size of
16 patients would be sufficient to reach a power of 80% to
detect relevant differences between exposition and control
at a two-sided α-level of 5% (nQueryAdvisor 6.0).
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